Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bimin Mixture II is an herbal medicine primarily indicated for the treatment of allergic rhinitis. It is understood to be a specific formulation of Bimin Kang Mixture (BMK), which comprises 18 herbal ingredients. The therapeutic action of Bimin Mixture II involves modulating the NF-κB signaling pathway, reducing inflammatory cell infiltration, regulating mucosal immune balance, and decreasing airway hypersensitivity. Key active components, such as quercetin, kaempferol, and luteolin, contribute to these effects by interacting with various inflammatory targets, including the IL-1β protein receptor, CXCL2, CCL20, PTGS2 (COX-2), and CXCL8. Inhibition of COX-2 expression is considered crucial for minimizing airway inflammation in allergic rhinitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bimin Mixture II.